CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Resveratrol +1 moredrug
Likely dose
Resveratrol 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01321151
NCT01321151Phase 2Completed

Use of Resveratrol to Decrease Secondary Brain Injury Following Sports-Related Concussions: a Double-Blind, Placebo-Controlled Study

University of Texas Southwestern Medical Center·interventional·Posted Mar 23, 2011·Updated Feb 11, 2021

In Brief

A Phase 2 clinical trial evaluating Resveratrol and Placebo for Sports Concussion. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Sports-related concussions are a serious problem in football, boxing, and other full contact sports. After experiencing consecutive concussions, there is an increase in neurological deficits that can lead to long-term cognitive problems (Dementia pugilistica). To combat this increase in brain damage, novel strategies need to be developed to protect athletes that are participating in these full contact sports. The purpose of this study is to elucidate whether resveratrol decreases brain injury and improves brain function after experiencing a concussion in boxers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 23, 2011
Enrollment StartMar 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.3 years ago

Interventions

Resveratroldrug

The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.

Placebodrug

The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.